medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2014, Number 1

<< Back Next >>

VacciMonitor 2014; 23 (1)

Validation of an ELISA for the quantification of protein impurities from host strain on the active principle of the Cuban recombinant vaccine against hepatitis B

Pérez E, Valderrama S, Baxera A, Jiménez Y, García G, Costa L, Quintana M

Language: Spanish
References: 18
Page: 11-16
PDF size: 247.64 Kb.


ABSTRACT

A double sandwich immunoassay was validated to quantify antibody protein impurities from host strain that can be present in the active pharmaceutical ingredient of Cuban vaccine against hepatitis B. All biological reagents used in the ELISA were prepared and characterized. The proteins from the host strain were obtained under the same conditions as the production process of the recombinant protein until a purification or primary semipurification step. The antisera addressed against those proteins were generated in rabbits by an immunization process in cascade. For validation the parameters analyzed were: linearity, limit of detection and quantification, accuracy, range and precision. The established assay was specific, and the calculated accuracy was from 89% to 109% for all studied buffers. A parabolic fit and a working range from 0.63 to 1.25 ng/mL were demonstrated. The repeatability and intermediate precision showed variation coefficients below 10% and 20% respectively.


REFERENCES

  1. International Conference on Harmonization (ICH). ICH Harmonized Tripartite Guideline. Comparability of Biotechnological/Biological products: Subject to Changes in Their Manufacturing Process Q5E CPMP/ICH/5721/03. Geneva: ICH; 2004.p.1-16. Disponible en: http://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/ Q5E_Guideline.pdf

  2. Schwertner D, Kirchner M. Are Generic HCP Assays Outdated? BioProcess International 2010;3(1):56-61.

  3. Kibbey M. Testing for Residual Host Cell Protein and DNA. Genetic Engineering and Biotechnology News 2013;33(9):1-5.

  4. Centro de Ingeniería Genética y Biotecnología. Procedimiento para realizar un proceso de obtención de un material de referencia de proteínas contaminantes utilizando la cepa MP- 36 de Pichia pastoris (PPO 4.26.591.99). Edición 02. La Habana: CIGB; 1999.

  5. Centro de Ingeniería Genética y Biotecnología. Métodos para la obtención de sueros anti-proteínas de la cepa hospedera en conejo (PPO 4.09.150.91). Edición 07. La Habana: CIGB; 2012.

  6. Centro de Ingeniería Genética y Biotecnología. Purificación de anticuerpos monoclonales anti-proteínas contaminantes de la cepa hospedera empleando columnas de inmunoafinidad (PPO 4.09.155.05). Edición 02. La Habana: CIGB; 2009.

  7. Nakane PK, Kawaoi A. Peroxidase-labeled antibody. A new method of conjugation. J Histochem Cytochem 1979;22:1084- 94.

  8. Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED). Regulación No. 37-2004: Buenas Prácticas de Laboratorio para el Control de Medicamentos. La Habana: Ediciones CECMED; 2004.

  9. International Conference on Harmonization (ICH). Harmonized Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2 (R1). Geneva: ICH; 2005.p.1-13.

  10. Wang X, Hunter AK, Mozier NM. Host Cell Proteins in Biologics Development: Identification, Quantitation and Risk Assessment. Biotechnology and Bioengineering 2009;103(3):446-58.

  11. Pérez EM, Díaz N, García A, Cruz A, Martínez Y, Gil M. Montaje y Validación de un ELISA para cuantificar impurezas proteicas de Escherichia coli (E. coli) en preparaciones de Interferón Alfa 2B Humano Recombinante. Rev Farm Bioquím Univ S Paulo 1997;33(2):77-83.

  12. Wang X, Schomogy T, Wells K, Mozier NM. Improved HCP Quantitation by Minimizing Antibody cross-reactivity to target proteins. BioProcess International 2010;8(1):18-24.

  13. Nims R, Nixon L. Our take on process-specific vs. generic host cell protein assay. RMC Pharmaceutical Solutions Blog 2011;8:1-3.

  14. Dagouassat N. Development of a quantitative assay for residual host cell proteins in a recombinant subunit vaccine against human respirator syncytial virus. Journal of Immunological Methods 2001;251(1-2):151-9.

  15. Briggs J, Panfili PR. Quantitation of DNA and Protein Impurities in Biopharmaceuticals. Anal Chem 1991;63:850-9.

  16. Rathore AS, Sobacke SE, Kocot TJ, Morga DR, Dufield RL, Mosier NM. Analysis for residual host cell proteins and DNA in process streams of a recombinant protein product expressed in Escherichia coli cells. J Pharm Biomed Anal 2003;32(6):1199- 211.

  17. Cygnus Technologies. Validation of package P. pastoris. In: Validation Summary Cygnus Technologies. Southport. Cygnus Editions, 2008. Disponible en: http// www.cygnustechnologies.com

  18. Savino E, Hu B, Sellers J, Sobjak A, Majewski N, Fenton S, et al. Development of an In-House, Process-Specific ELISA for Detecting HCP in Therapeutic Antibody, Part 1. BioProcess International 2011;9(3):38-47.




2020     |     www.medigraphic.com